Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort
To assess the comparative effectiveness of febuxostat and allopurinol in reducing serum urate (sUA) levels in a real-world U.S. managed care setting. This retrospective study utilized 2009 to 2012 medical and pharmacy claims and laboratory data from a large U.S. commercial and Medicare Advantage hea...
Risk of renal disease was almost 40% lower
Allopurinol trumps Febuxostat for renal protection, but this is a retrospective cohort study. But with such stark differences, would Febuxostat go head-to-head against Allopurinol in a prospective study, looking at kidney failure and other important outcomes like cardiovascular events and fatty liver?
Comparative effectiveness of allopurinol versus febuxostat for preventing incident renal disease in older adults: an analysis of Medicare claims data
Objective To assess the comparative effectiveness of allopurinol versus febuxostat for preventing incident renal disease in elderly. Methods In a retrospective cohort study using 2006–2012 Medicare claims data, we included patients newly treated with allopurinol or febuxostat (baseline period of 183...
I used to assume that the reversal of mild to moderate chronic kidney disease with urate lowering therapy was a class effect, in that the benefit stemmed from urate reduction rather than what drug was used to achieve that effect.
And that the more expensive a drug is, the better it works?
Are allopurinol dose and duration of use nephroprotective in the elderly? A Medicare claims study of allopurinol use and incident renal failure
Objective To assess the effect of allopurinol dose/duration on the risk of renal failure in the elderly with allopurinol use. Methods We used the 5% random Medicare claims data from 2006 to 2012. Multivariable-adjusted Cox regression analyses assessed the association of allopurinol dose/duration wit...
The answer is apparently yes: duration and dose of Allopurinol use correlates with less chronic kidney disease.
This should put paid to the common misconception that prolonged Allopurinol use may damage the kidneys.
Few studies, if any, have examined cardiovascular outcomes in patients with diabetes and gout. Both…
Current Allopurinol use among diabetics with gout was associated with a third reduction in risk for heart attack compared to those who stopped medication.
Allopurinol and the risk of incident peripheral arterial disease in the elderly: a US Medicare claims data study
MADRID – The gout drug’s tie to fewer arrhythmias…